Peter Attia MD278 ‒ Breast cancer: how to catch, treat, and survive breast cancer | Harold Burstein, M.D., Ph.D.
CHAPTERS
- 0:00 – 3:35
Breast Cancer Prevalence and Guest Background
Harold Burstein notes breast cancer is the most commonly diagnosed cancer in most countries. Peter Attia introduces the topic and Burstein describes his oncology role at Dana-Farber. They cover the one-in-eight lifetime risk and the roughly 275,000 cases and 38,000 deaths per year in the U.S.
- •Breast cancer is the most common cancer diagnosis in the world excluding non-melanoma skin cancer, though lung cancer still causes more deaths
- •American women have about a one in eight (12%) lifetime risk
- •About 275,000 U.S. cases and 38,000 deaths yearly, meaning roughly 80-85% are cured
- •Burstein is a Harvard professor and medical oncologist at Dana-Farber involved in guidelines work
- 3:35 – 14:54
Breast Anatomy, Development, and Environmental Risk Factors
Burstein explains the breast as a gland and how puberty, reproductive history and nutrition shape cancer risk. They discuss migration studies, nuns and pregnancy history, and the gap between population risk and individual risk.
- •Breast cancer arises from glandular tissue, like many common cancers
- •Earlier puberty, longer menstruation, fewer children and shorter nursing are thought to contribute to rising rates
- •Rates rise when populations move to or become more like Western societies
- •Risk factors raise individual risk modestly, e.g. from about 12% to 15%
- 14:54 – 20:03
The Three Main Subtypes of Breast Cancer
Burstein lays out the three flavors of breast cancer and Attia clarifies each one. They cover ER-positive/HER2-negative, triple-negative, and HER2-positive disease, with their demographics and why HER2 matters for targeted therapy.
- •ER-positive, HER2-negative tumors are 70-75% or more, peak around age 65, and are often found on mammography
- •Triple-negative tumors are about 10-15%, skew younger, are more common in African American women and BRCA1 carriers
- •HER2-positive tumors are about 15% and are split between ER-positive and ER-negative
- •Trastuzumab (Herceptin) is the targeted therapy for HER2-positive disease
- 20:03 – 23:24
Menopause, Breast Density, Obesity, and Smoking
Attia asks what happens to the breast after menopause. Burstein says density is a marker of slightly higher risk and that breast size is not itself a driver. Obesity is a weak risk factor and smoking is not a major one.
- •Higher breast density is associated with slightly greater risk beyond making cancers harder to see
- •Breast size does not fundamentally affect risk
- •Obesity is a weak but detectable risk factor and cannot be used to stratify screening
- •Smoking is not a major risk factor for breast cancer
- 23:24 – 31:13
Breast Lumps, Self-Exams, and Biopsy
The conversation turns to breast lumps, normal lumpiness and self-exams. Burstein says body awareness matters more than rigid self-exam, and describes imaging and core needle biopsy, noting most findings are not cancer.
- •Breast tissue is normally lumpy; patients should know what is normal for them
- •Studies of formal self-exam training in China did not change mortality, but awareness of changes does matter
- •Findings that are suspicious get imaging and, if needed, an image-guided core needle biopsy
- •Most findings turn out benign or precancerous
- 31:13 – 38:51
Precancerous Changes and DCIS: Diagnosis and Surgical Management
Burstein explains ducts versus lobules and the progression from atypical hyperplasia to in situ carcinoma. They discuss DCIS as a stage zero lesion found by mammography, with excision, upstaging and sentinel node considerations.
- •ADH and ALH are precursor lesions with roughly a half to 1% per year risk of breast cancer
- •DCIS is stage zero, likened to a colon polyp, and is mostly found through mammographic calcifications
- •About 15-20% of DCIS excisions reveal a small invasive component
- •Sentinel node mapping is done with mastectomy for DCIS since it can't be done later
- 38:51 – 57:44
DCIS After Surgery: Radiation, Anti-Estrogens, and Overtreatment Questions
Burstein covers standard options after lumpectomy for DCIS, recurrence risks, and why treating DCIS has never been shown to affect mortality. They discuss active surveillance trials, the safety and duration of modern radiation, and the small absolute benefit of tamoxifen.
- •Radiation lowers in-breast recurrence into the low single digits; DCIS treatment has never shown a survival benefit
- •Active surveillance trials led by Shelley Hwang are testing doing less
- •Modern tangential radiation and breath-holding make heart risk very low
- •NSABP B-24 showed tamoxifen halves risk, but the modern absolute benefit is about 3-5%
- •Radiation courses are shortening from 25 to 16 fractions, with interest in five days
- 57:44 – 1:07:41
LCIS and the Tamoxifen Prevention Trial
Attia asks about LCIS, and Burstein explains it is a field risk marker rather than a lesion treated with surgery and radiation. The NSABP P-1 trial showed tamoxifen cut breast cancer diagnoses in half in higher-risk women without a survival benefit, prompting discussion of consent and side effects.
- •LCIS is managed with close monitoring and possible anti-estrogens, not the DCIS approach
- •LCIS is about 20% as common as DCIS and nearly always ER-positive
- •In P-1, tamoxifen cut diagnoses from about 4% to about 2% over five years but did not improve survival
- •Burstein says anti-estrogens have cured more people than almost anything in oncology except surgery
- 1:07:41 – 1:17:30
Overdiagnosis and Screening Imaging: Mammography, Ultrasound, MRI, BI-RADS
Burstein explains that more DCIS and LCIS is a natural result of successful screening. The discussion covers mammography as the main tool, supplemental ultrasound and MRI for higher-risk women, and BI-RADS scoring.
- •Successful screening programs find precancerous lesions, as with Pap smears and colonoscopy
- •Mammography is the main screening tool; MRI is routine for very high-risk women such as BRCA carriers
- •BI-RADS scores range from 0 to 5 and are well standardized
- •Imaging does not give the resolution that prostate MRI does; the biopsy guides management
- 1:17:30 – 1:28:03
Invasive Breast Cancer: Pathology, Surgery, and Staging
Burstein describes what a core biopsy reports and the move toward lumpectomy with sentinel node biopsy. They cover staging by tumor size, nodes and biology, with approximate survival figures by stage and for stage IV.
- •Pathology reports grade, ER, PR, HER2, and sometimes Ki-67, TILs and lymphovascular invasion
- •Most women with early detection are candidates for lumpectomy
- •Stage I is 2 cm or smaller with negative nodes; lymph node involvement is the biggest prognostic marker
- •Ballpark 10-year survival is 90%+ for stage I, 75-80% for II, 65-75% for III
- •Median survival for stage IV is about five years, longer in HER2-positive disease
- 1:28:03 – 1:33:31
The Case for Aggressive Screening and Global Impact
Attia argues that catching tumors early should cure more women, and Burstein agrees while noting ongoing debate. Burstein says breast cancer is becoming a growing global burden where AI-assisted imaging may help.
- •Attia argues tumor burden matters, so earlier detection shifts women toward stage I
- •Burstein agrees but notes most screening trials ended by the late 1980s and treatment has improved
- •Breast cancer is the most diagnosed cancer worldwide as countries become more affluent
- •AI imaging research may help where there are too few radiologists
- 1:33:31 – 1:48:30
Adjuvant and Neoadjuvant Treatment by Subtype
Burstein explains adjuvant therapy and the two drivers of falling mortality: early detection and systemic therapy. They cover endocrine therapy, chemotherapy, immunotherapy, trastuzumab and CDK4/6 inhibitors, and neoadjuvant therapy with pathologic complete response.
- •Early detection and effective systemic therapy each account for about half of the mortality improvement
- •Genomic tests like Oncotype DX let about two-thirds of women avoid chemotherapy in ER-positive disease
- •Chemotherapy drugs are blunt anti-proliferative agents, with supportive care much improved
- •Immunotherapy for triple-negative and trastuzumab/pertuzumab for HER2-positive have changed outcomes
- •Neoadjuvant therapy allows less surgery and shows response; residual disease may get further drugs
- 1:48:30 – 1:52:32
Hormone Replacement Therapy After Breast Cancer
Attia asks, using the prostate cancer analogy, whether women in remission can use estrogen replacement. Burstein describes anti-estrogen side effects and why most breast cancer patients avoid oral hormone replacement, favoring non-hormonal options and vaginal estrogen.
- •Anti-estrogen side effects include hot flashes, joint aches, vaginal dryness and osteoporosis
- •Anti-estrogens are not usually omitted even after complete pathologic response in ER-positive tumors
- •Non-hormonal options exist for osteoporosis and hot flashes
- •Vaginal estrogen is used fairly liberally; a few women need systemic hormones for quality of life
- 1:52:32 – 2:01:53
Hereditary Breast Cancer and Genetic Testing
Burstein explains that 8-10% of breast cancers are hereditary, with BRCA1/2 accounting for about half. They cover BRCA biology, risk-reduction options, PALB2, CHEK2 and ATM, and the role of genetic counselors and testing panels.
- •BRCA1/2 carriers may face a one in two to two in three lifetime breast cancer risk
- •Options include mastectomy, oophorectomy, or intensified screening alternating MRI and mammography
- •BRCA mutations are autosomal dominant loss-of-function mutations affecting DNA repair
- •PALB2, CHEK2 and ATM make up much of the rest of hereditary cases
- •Burstein favors genetic counselors over over-the-counter tests for family history concerns
- 2:01:53 – 2:13:05
Multidisciplinary Care and Choosing Where to Be Treated
Attia asks about multidisciplinary care and where patients should be treated. Burstein says the key is that providers work as a team, and both discuss second opinions, tumor boards and pathology review.
- •Multidisciplinary care brings together surgery, radiation, medical oncology, pathology, genetics and imaging
- •Patients can tell whether providers are talking to each other
- •Excellent breast cancer care is available in many parts of the country; a second opinion is a good idea if there is ambiguity
- •Pathology and radiology review and reconstructive surgery coordination can vary
- •Attia suggests having pathology slides sent for a second review
- 2:13:05 – 2:17:14
Breast Cancer in Men and Closing Thoughts
Burstein explains that male breast cancer is about one in 200 cases, is often caught later, and is nearly always estrogen receptor-positive. The episode closes with Attia's hope that listeners can advocate for themselves and Burstein's optimism about improving outcomes.
- •Male breast cancer is about 1 per 200 female cases, with genetic predisposition among risk factors
- •Men are often diagnosed at higher stages because they are unaware of the risk
- •Treatment principles are similar to women's, and most male tumors are ER-positive
- •Burstein closes by noting women are doing better and better with early detection and improving drugs
